Nomura Securities Maintains a 'Neutral' on rue21, inc. (RUE); Q2 Results Review
Get Alerts RUE Hot Sheet
Price: $41.99 --0%
Rating Summary:
1 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 19
Rating Summary:
1 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 19
Join SI Premium – FREE
Nomura Securities maintains a 'Neutral' on rue21, inc. (NASDAQ: RUE), price target lowere from $34 to $30.
Nomura analyst, Paul Lejuez, said, "2Q results were not as bad as it appears on the surface. Comps and EPS were somewhat disappointing, but GM improved on better full-priced selling and no costing pressures. Top line was hurt by lack of Summer clearance during the heat wave in July, but back-to-school seems to be off to a good start. We are revising our F11E EPS to $1.51 from $1.59 based on lower-than expected sales, and reducing our TP to $30, which represents 6.8x our F12 EBITDA vs. the group at 6.1x (we view a slight premium multiple as reasonable for this teen growth story). The risk/reward seems balanced at current levels."
For more ratings news on rue21, inc. click here and for the rating history of rue21, inc. click here.
Shares of rue21, inc. closed at $26.97 yesterday.
Nomura analyst, Paul Lejuez, said, "2Q results were not as bad as it appears on the surface. Comps and EPS were somewhat disappointing, but GM improved on better full-priced selling and no costing pressures. Top line was hurt by lack of Summer clearance during the heat wave in July, but back-to-school seems to be off to a good start. We are revising our F11E EPS to $1.51 from $1.59 based on lower-than expected sales, and reducing our TP to $30, which represents 6.8x our F12 EBITDA vs. the group at 6.1x (we view a slight premium multiple as reasonable for this teen growth story). The risk/reward seems balanced at current levels."
For more ratings news on rue21, inc. click here and for the rating history of rue21, inc. click here.
Shares of rue21, inc. closed at $26.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Downgrades Workday (WDAY) to Hold
- Agios Pharma (AGIO) Reiterated at Overweight by Cantor Fitzgerald on Thalassemia Opportunity
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
NomuraSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share